1 Predictors for participation in DNA self-sampling of childhood cancer survivors in

2 Switzerland

- 3 Nicolas Waespe, MD,^{1,2,3} Sven Strebel, MSc Pharm,^{1,2,4} Denis Marino MSc,² Veneranda
- 4 Mattiello, MD,^{2,5} Fanny Muet, MSc,² Tiago Nava, MD,^{2,5} Christina Schindera, MD,^{1,6}
- 5 Fabien N. Belle, PhD,^{1,7} Luzius Mader, PhD,¹ Adrian Spoerri, PhD, MPH,⁸ Claudia E.
- 6 Kuehni, MD, MSc,^{1,9,*} Marc Ansari, MD.^{2,5,*}
- 7
- 8 *) Shared equally contributing senior authors.
- 9 ¹Childhood Cancer Research Group, Institute of Social and Preventive Medicine,
- 10 University of Bern, Bern, Switzerland;
- ¹¹ ² CANSEARCH research platform for paediatric oncology and haematology, Faculty of
- 12 Medicine, Department of Pediatrics, Gynecology and Obstetrics, of the University of
- 13 Geneva, Geneva, Switzerland;
- ¹⁴ ³ Graduate School for Cellular and Biomedical Sciences (GCB), University of Bern,
- 15 Bern, Switzerland;
- ⁴ Graduate School for Health Sciences (GHS), University of Bern, Bern, Switzerland;
- ⁵ Division of Pediatric Oncology and Hematology, Department of Women, Children,
- 18 and Adolescents, University Hospital of Geneva, Geneva, Switzerland;
- ⁶ Pediatric Oncology/Hematology, University Children's Hospital Basel, University of
- 20 Basel, Basel, Switzerland;
- 21 ⁷ Center for Primary Care and Public Health (Unisanté), Institute of Social and
- 22 Preventive Medicine (IUMSP), University of Lausanne, Lausanne, Switzerland; NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- ⁸ SwissRDL Medical Registries and Data Linkage, Institute of Social and Preventive
- 24 Medicine, University of Bern, Bern, Switzerland;
- ⁹ Division of Pediatric Oncology and Hematology, Department of Pediatrics,
- 26 University Hospital of Bern, Bern, Switzerland.
- 27
- 28 Corresponding author: Prof. Dr. med. Marc Ansari, MD; Division of Pediatric
- 29 Oncology and Hematology, Department of Women, Children, and Adolescents,
- 30 University Hospital of Geneva, Rue Willy-Donzé 6; Bureau 5-507; 1211 Genève,
- 31 Switzerland; T: +41 22 372 47 31; F : +41 22 382 31 00
- 32 E-mail : <u>marc.ansari@hcuge.ch</u>
- 33
- 34 Word count Abstract: (200/ 200, unstructured)
- 35 Word count Main Text: (1987/ max. 2000 words)
- 36 Number of Tables and Figures: (2/ 2 max)
- 37 Number of Supporting Information files: (1/open)
- 38 References: (18/20)
- 39 Short running title: Participation in DNA self-sampling

40

Key words (max 3-10): childhood cancer, cancer survivors, DNA, cohort study, drug
side effects, second primary neoplasm, genetic predisposition, registry, genetic testing,
genetic polymorphism.

44 ABSTRACT

45	Research on germline genetic variants relies on a sufficient number of eligible
46	participants which is difficult to achieve for rare diseases such as childhood cancer.
47	With self-collection kits using saliva or buccal swabs, participants can contribute
48	genetic samples conveniently from their home. We identified determinants of
49	participation in DNA self-collection in this cross-sectional study.
50	We invited 928 childhood cancer survivors in Switzerland with a median age of 26.5
51	years (interquartile range 18.8-36.5), of which 463 (50%) participated. Foreign
52	nationality (odds ratio [OR] 0.5, 95%-confidence interval [CI] 0.4-0.7), survivors aged
53	30-39 years at study versus other age groups (OR 0.5, CI 0.4-0.8), and those with a
54	known cancer predisposition syndrome (OR 0.5, CI 0.3-1.0) participated less. Survivors
55	with a second primary neoplasm (OR 1.9, CI 1.0-3.8) or those living in a French or
56	Italian speaking region (OR 1.3, 1.0-1.8) tended to participate more.
57	We showed that half of survivors participate in germline DNA self-sampling relying
58	completely on mailing of sample kits. Foreign nationality, age 30-39 years, and cancer
59	predisposition syndromes were associated with less participation. More targeted
60	recruitment strategies may be advocated for these subgroups. To increase participation
61	in DNA self-sampling, understanding and perceptions of survivors need to be better
62	understood.
63	

64

66 MAIN MANUSCRIPT

67 1. INTRODUCTION

68 Cancer survivorship and associated health complications have become increasingly 69 important with improved childhood cancer survival.[1] Chronic conditions like cardiac, pulmonary, auditory, endocrine, reproductive, and neurocognitive complications, and 70 71 second primary neoplasms (SPNs) are gaining importance in research and clinical care.[2] 72 By age 50 years, childhood cancer survivors have twice as many severe chronic health 73 conditions compared to controls.[3] Mortality in survivors is more than 10-times higher 74 than in the general population.[4] While many demographic, clinical, and treatment-75 related risk factors are known, the contribution of genetic variation in the development of 76 health complications is still poorly understood. Therefore, research group collect germline DNA samples systematically to enable research on genetic risk factors.[5–7] 77

Self-sampling of germline DNA by participants has increased the reach of sample 78 79 collection because many do not attend regular medical care. Since the 1990's buccal 80 swabs are used. In the 2010's saliva collection kits became widely available which are 81 easy to use and yield DNA of good quality and sufficient quantity.[8] Saliva collection 82 kits do not need time-sensitive processing or cooling like blood, but can be collected, transported, and stored in ambient conditions for years. Collection of saliva samples by 83 84 participants themselves is feasible and effective.[5] Self-collection may, however, be affected by participation bias. Ness et al. identified female sex, white race/ethnicity, 85 86 college graduation, never smoking, accessing the healthcare system in the past 2 years, 87 and having a second malignant neoplasm as predictors for participating in saliva sample 88 self-collection.[5] Outside of the US, predictors for participation in childhood cancer survivors have not been studied. They might differ based on the perception of the 89

90	healthcare system and acceptance of genetic research. We assessed the response rate and
91	investigated predictors for participation in saliva self-sampling in Switzerland as part of
92	the national Germline DNA Biobanking for Childhood Cancer and Blood Disorders
93	(BISKIDS) project.

- 94
- 95
- 96 2. METHODS
- 97 2.1. Study design

We used contact information from the Swiss Childhood Cancer Registry (SCCR) at the Institute of Social and Preventive Medicine, University of Bern, Switzerland to invite childhood cancer survivors for germline DNA self-collection in this cross-sectional study design. Addresses were collected from hospitals involved in primary and follow-up care and updated through the Swiss national postal service.

103 We obtained data on patient characteristics from the SCCR. In September 2019, participants received self-sampling kits by postal mail at their home and were asked to 104 105 send them to the germline DNA Biobank Switzerland for Childhood Cancer and Blood 106 Disorders (BISKIDS), which is part of the Paediatric Biobank for Research in 107 Haematology and Oncology (BaHOP) Geneva, Switzerland. BaHOP was awarded a 108 VITA label from **Biobanking** Platform the **Swiss** (SBP; 109 www.biobanksqan.ch/#/biobanks/3919; bbmri-110 eric:ID:CH HopitauxUniversitairesGeneve:collection:CH BaHOP). All participants 111 received an informed consent form together with the saliva kit. The Geneva Cantonal

112 Commission for Research Ethics has approved the BaHOP biobank (approval PB_2017-

113	00533)	and	the	associated	"Genetic	Risks	for	Childhood	Cancer	Complications
114	Switzerl	land (GEC	COS)" stud	y, which w	vill utili	ize th	e samples (a	approval	2020-01723).

115

116

117 2.2. Study population

118 Eligible for invitation to our study were participants who were: (i) registered in SCCR; 119 (ii) Swiss residents; (iii) treated in one of nine paediatric hospitals caring for children with 120 cancers; (iv) diagnosed with a neoplasm according to the International Classification of Childhood Cancers, 3rd edition (ICCC-3), or Langerhans cell histiocytosis before age 21 121 122 years from 1976 to 2017; (v) exposed to lung toxic (chest radiotherapy) or ototoxic 123 treatment (brain radiotherapy with ≥ 30 Gray or platinum chemotherapy); and (vi) survivors of 2 years or more since childhood cancer diagnosis as of July 2019. We 124 125 excluded participants who: (I) had declined participation in research projects; (II) had 126 died; or (III) did not have a valid address in Switzerland.

127

128 2.3. Outcome definition and clinical characteristics

Our main outcome was participation in the germline DNA sample collection, defined as returning the DNA sample and the signed consent form. Non-participation was defined as active decline or non-response until December 2020 (end of follow-up). Clinical information was extracted from the SCCR. We recorded the age at first neoplasm in 5year groups, calendar year at first neoplasm diagnosis and age at survey in 10-year groups, and the ICCC-3 main category [9] of the first neoplasm. Chemotherapy, radiotherapy,

135	and haematopoietic stem cell transplantation were classified as "yes" if given during the
136	first neoplasm treatment. We classified cancer predisposition syndrome and second
137	primary neoplasms as previously described.[10]
138	
139	

140

141 2.4. Sample collection

142 Survivors received by postal mail a letter with information on the planned DNA sample 143 collection, and a form with which they could opt and a prepaid return envelope. Those who did not opt out received 3 weeks later a parcel including (i) detailed information on 144 145 the biobanking project and an informed consent form to sign, (ii) one Oragene DNA OG-146 500 saliva sampling kit (manufactured by DNA Genotek, Ottawa, Ontario, Canada) with 147 material for return by regular mail (liquid-tight bio-specimen bag, bubble wrap), (iii) 148 information on saliva sample collection and shipment provided by the manufacturer 149 (www.dnagenotek.com/row/products/collection-human/oragene-dna/500-series/OG-150 500.html), (iv) a graphical abstract of the workflow of saliva collection and return of samples and consent forms, and (v) prepaid return envelopes for return of the consent 151 152 form and the saliva sample. We sent two letters as reminders to those who did not return 153 the sample, one after 6 weeks and another one after 8 weeks.

We offered participants the opportunity to receive additional information through (i) a project specific e-mail address, and (ii) a dedicated telephone hotline. Both were operated by the study coordinator, a trained specialist in paediatric haematology and oncology with experience in cancer genetics, or biobank staff in case of absence.

158

159

160 2.5. Statistical analysis

We compared demographic, neoplasm, treatment, and follow-up information of 161 162 participants with non-participants. Univariable logistic regression and multivariable 163 logistic regression models were fitted to identify determinants of participation. Covariates 164 were kept in the multivariable logistic regression model using backward selection. We 165 removed covariates with $p \ge 0.2$. We additionally adjusted for sex and age at first primary 166 neoplasm diagnosis in the model. We used the software Stata version 15 (Stata 167 Corporation, Austin, Texas) for analyses. Statistical uncertainty of estimates was expressed as 95%-confidence intervals. 168

169

170

171 **3. RESULTS**

172 **3.1. Characteristics of cohort**

173 We traced and contacted 928 of 1,215 eligible childhood cancer survivors (Figure 1).

174 Of those we contacted, 463 (50%) returned a germline DNA sample. Median age at

- diagnosis was 8.7 years (interquartile range [IQR] 3-13) and at invitation 26.5 years
- 176 (IQR 19-37; **Table 1**). The most common diagnoses were central nervous system
- 177 tumours (28%) and lymphomas (21%) which reflected our selection process of inviting
- 178 former childhood cancer patients with pulmotoxic and ototoxic treatments. Most
- 179 patients had been treated with chemotherapy, about two thirds with radiotherapy, and a

- 180 minority with haematopoietic stem cell transplantation. Relapse had been confirmed in
- 181 21% of survivors, a second primary neoplasm in 4% and a cancer predisposition
- 182 syndrome (CPS) in 5%. Survivors were predominantly from the German (n=633, 68%)
- language region and the remaining from the French (n=262, 28%) and Italian (33, 4%)
- 184 language region, which roughly reflects the language distribution in Switzerland.

	Participation			Univariable logist regression	tic	Multivariable log	gistic
Characteristic	Total (n, %) ^a	Yes (n, %) ^a	No (n, %) ^a	OR (95%-CI)	p-value	OR (95%-CI)	p-value
Sex							
Female	426 (46)	209 (45)	217 (47)	Ref.		Ref.	
Male	502 (54)	254 (55)	248 (53)	1.06 (0.82 - 1.38)	0.64	1.09 (0.83-1.42)	0.53
Nationality							
Swiss	710 (76)	377 (81)	333 (72)	Ref.		Ref.	
Foreign	218 (24)	86 (19)	132 (28)	0.58 (0.42-0.78)	< 0.001	0.53 (0.38-0.73)	<0.001
Correspondence language							
German	633 (68)	308 (67)	325 (70)	Ref.		Ref.	
French and Italian	295 (32)	155 (34)	140 (30)	1.17 (0.89-1.54)	0.27	1.31 (0.98-1.75)	0.07
Age at first neoplasm diagnosis							
Median (IQR, years)	8.7 (3.0-13.4)	8.7 (3.0-13.4)	8.6 (3.6-13.3)				
0-4 years	311 (34)	166 (36)	145 (31)	1.14 (0.83 – 1.57)	0.35	1.08 (0.75-1.56)	0.4
5-9 years	212 (23)	97 (21)	115 (25)	0.84 (0.59 - 1.20)		0.79 (0.54-1.14)	
10-14 years	287 (31)	144 (31)	143 (31)	Ref.		Ref.	
15-20 years	118 (13)	56 (12)	62 (13)	0.90 (0.58 - 1.38)		0.95 (0.61-1.48)	
Year of diagnosis							
1976-1985	110 (12)	54 (12)	56 (12)	0.84 (0.55 - 1.30)	0.02	‡	
1986-1995	193 (21)	78 (17)	115 (25)	0.59 (0.41 - 0.85)		‡	
1996-2005	312 (34)	164 (35)	148 (32)	0.97 (0.71 - 1.33)		‡	
2006-2016	313 (34)	167 (36)	146 (31)	Ref.		‡	

Table 1: Characteristics of 928 Swiss childhood cancer survivors invited to home collection of germline DNA, stratified by participation status.

Diagnostic group of first primary neo	oplasm (ICCC-3)				
Leukaemias, myeloproliferative and myelodysplastic diseases	35 (4)	14 (3)	21 (5)	0.77 (0.37-1.58)	0.38
Lymphomas	190 (21)	95 (21)	95 (20)	1.15 (0.79-1.68)	
CNS tumours and miscellaneous intracranial and intraspinal neoplasms	256 (28)	119 (26)	137 (30)	Ref.	
Neuroblastoma and other peripheral nervous cell tumours	78 (8)	45 (10)	33 (7)	1.57 (0.94-2.62)	
Retinoblastoma	44 (5)	18 (4)	26 (6)	0.8 (0.42-1.53)	
Renal tumours	33 (4)	20 (4)	13 (3)	1.77 (0.85-3.71)	
Hepatic tumours	24 (3)	15 (3)	9 (2)	1.92 (0.81-4.54)	
Malignant bone tumours	100 (11)	56 (12)	44 (10)	1.47 (0.92-2.33)	
Soft tissue and other extraosseous sarcomas	94 (10)	48 (10)	46 (10)	1.2 (0.75-1.93)	
Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	64 (7)	29 (6)	35 (8)	0.95 (0.55-1.65)	
Other malignant epithelial neoplasms and malignant melanomas	6 (1)	2 (<1)	4 (1)	0.58 (0.1-3.2)	
Langerhans cell histiocytosis	4 (<1)	2 (<1)	2 (<1)	1.15 (0.16-8.3)	
Chemotherapy					
No	61 (7)	25 (5)	36 (8)	Ref.	
Yes	867 (93)	438 (95)	429 (92)	1.47 (0.87-2.49)	0.15
- With platinum agents	491 (54)	259 (56)	232 (50)	1.27 (0.98-1.64)	0.07
Radiotherapy					
No	319 (34)	160 (35)	159 (34)	Ref.	
Yes	609 (66)	303 (65)	306 (66)	0.98 (0.75-1.29)	0.91
- With head radiotherapy (≥30 Gy)	343 (37)	166 (36)	177 (38)	0.91 (0.70-1.19)	0.49
- With chest radiotherapy	328 (35)	156 (34)	172 (37)	0.87 (0.66-1.33)	0.29

Haematopoietic stem cell transplar	ntation						
No	864 (93)	428 (92)	436 (94)	Ref.			
Yes	64 (7)	35 (8)	29 (6)	1.23 (0.74-2.05)	0.43		
Relapse of first neoplasm							
No	738 (80)	368 (80)	370 (80)	Ref.			
Yes	190 (21)	95 (21)	95 (20)	1.01 (0.73-1.38)	0.97		
Cancer predisposition syndrome							
No	879 (95)	442 (96)	437 (94)	Ref.		Ref.	
Yes	49 (5)	21 (5)	28 (6)	0.74 (0.42-1.33)	0.31	0.54 (0.29-1.0)	0.05
Second primary neoplasm							
No	889 (96)	438 (95)	451 (97)	Ref.		Ref.	
Yes	39 (4)	25 (5)	14 (3)	1.84 (0.94-3.58)	0.07	1.92 (0.97-3.82)	0.06
Age at study invitation							
Median (IQR, years)	26.5 (18.8-36.5)	25.1 (18.3-35.2)	27.7 (19.5-37.3)				
<10 years	50 (5)	23 (5)	27 (6)	0.72 (0.4-1.32)	0.005	0.75 (0.39-1.43)	0.002
10-19 years	215 (23)	121 (26)	94 (20)	1.09 (0.77-1.56)		1.17 (0.81-1.70)	
20-29 years	296 (32)	160 (35)	136 (29)	Ref.		Ref.	
30-39 years	198 (21)	78 (17)	120 (26)	0.55 (0.38-0.8)		0.54 (0.38-0.79)	
40 or more years	169 (18)	81 (18)	88 (19)	0.78 (0.54-1.14)		0.72 (0.48-1.07)	

Legend: ‡, omitted from multivariable regression model for collinearity with age at study invitation; CNS, central nervous system; ICCC-3, international

188 classification of childhood cancer, edition 3; IQR, interquartile range; n, number

189 3.2. Recruitment and impact of reminders

190 We invited 928 survivors for home saliva collection. After the first information letter, 191 64 (7%) actively declined participation through an opt-out reply form. The remaining 192 864 survivors received a saliva sampling kit and an informed consent form. Seventyseven of those actively refused participation (8%) and 324 eligible survivors did not 193 194 answer (35%). Within 6 weeks after the send out of the sampling kit, 291 (63%) 195 participated (Supplementary Figure 1). The first reminder letter led to 117 additional 196 participants (25%) and the second reminder to an additional 55 participants (12%). On 197 the consent form, 383 (83%) indicated that they wanted to be informed about potential 198 incidental findings and 394 (85%) agreed that their samples could be used after death.

199

3.3. Covariates associated with participation

201 Foreign nationality (odds ratio [OR] 0.5, 95%-confidence interval [CI] 0.4-0.7) and age 202 at study were associated with non-participation. Survivors aged 30-39 years participated 203 least (OR 0.5, CI 0.4-0.8), those 10-29 years tended to participate best, and those <10 204 years and >40 years in between. Those with a cancer predisposition syndrome tended to 205 participate less (OR 0.5, CI 0.3-1.0), while survivors with a diagnosis of a second 206 primary neoplasm (OR 1.9, CI 1.0-3.8) and those who spoke French or Italian (OR 1.3, CI 1.0-1.8) tended to participate more. There were no differences in sex, age at first 207 208 primary neoplasm diagnosis, diagnostic groups, treatments, and relapse of first primary 209 neoplasm between participants and non-participants.

210

212 4. **DISCUSSION**

213	This study described participation of Swiss childhood cancer survivors in home saliva
214	collection for germline DNA extraction. We confirmed previous findings of about 50%
215	participation in home DNA self-collection. Foreign nationality was a strong predictor
216	for non-participation. Survivors with known CPSs and aged 30-39 years were also less
217	likely to participate. In contrast, survivors with second primary neoplasms were more
218	likely to participate. Most participating survivors wanted to be informed about
219	incidental findings that might be relevant to their health and most agreed to their
220	samples being available for research after their death.
221	
222	The overall response rate of 50% was comparable to other DNA sample self-collections
223	from home. Ness et al. reported 54% participation on 10,356 eligible adult childhood
224	cancer survivors[5] and Dykema found 54% participation in 8,081 adults in the
225	Wisconsin Longitudinal Study.[11] Nishita et al. offered an incentive of 25US\$ for
226	returning a saliva sample which led to 59% participation of 967 adults in a smoking
227	cessation trial, which was only slightly higher than in studies without incentive.[12]
228	Lower participation was found in genetic assessment of preterm birth where 23% of 708
229	mothers participated.[13] Higher participation rates were achieved in an active clinical
230	setting with patient-caregiver interaction where 97% of 155 adults from the US
231	participated.[14]

232

Foreign nationality was strongly associated with non-participation in concordance with a previous study from our group on response to questionnaire studies.[15] This could be

related to language issues affecting understanding or reluctance to participate in 235 236 research due to lower confidence in research. Foreign nationality is also linked to lower 237 socioeconomic status, which was a predictor for lower participation in research.[16] 238 Easy to understand information material, maybe in more languages, and information by 239 phone might counteract these differences in participation. Our findings on language 240 difference were in contrast to a large Swiss survey on willingness to participate in 241 personalized health research, [16] and our group's previous publication on participation 242 in a questionnaire study, [15] where German speaking people were more likely to 243 participate. The former was sent from the previously treating institutions and the latter 244 form a German speaking research institution. In our study, the invitation was sent off 245 from Geneva hospital, situated in the French speaking language region, which might 246 have improved acceptance of the study of the CCS living in this language region. 247 Survivors with known CPSs were less willing to participate in our study. Reasons could be the impression of futility as participants were already investigated, fear of further 248 249 findings, or bad experiences with genetic workup. Survivors with second primary 250 neoplasms tended to participate more, potentially because they were seeking 251 explanations for their multiple neoplasms. Lower participation in older survivors might 252 be reflective of being more distanced to the previous disease or in a busy phase of their 253 lives (caring for children and being active at work).

254

A limitation of our study was the lack of information on reasons for non-participation.

256 We further did not send additional sampling kits with reminders which might have

257 prevented survivors from participating who had discarded their kit already. Strengths

258 were the availability of clinical information including CPSs. Our results of the study are

- 259 likely representative for childhood cancer survivors in other countries with similar trust
- 260 in healthcare institutions and responsible (genetic) research.

261

- 262 Our study illustrates that home saliva collection through a process completely relying
- 263 on mail is feasible and yields a response rate of about 50%. Specific survivor groups
- 264 (foreign nationality, age 30-39 years, and patients with cancer predisposition
- 265 syndromes) were less likely to participate which needs to be taken into account when
- studies are planned.

267

269 Abbreviations table:

270	BaHOP	Biobank for Hematology and Oncology in Pediatrics
271	BISKIDS	Germline DNA Biobank Switzerland for Childhood Cancer and
272		Blood Disorders
273	CCS	Childhood cancer survivor
274	CNS	Central nervous system
275	CPS	Cancer predisposition syndrome
276	DNA	Deoxyribonucleic acid
277	GECCOS	Genetic risks for childhood cancer complications Switzerland
278	HSCT	Hematopoietic stem cell transplantation
279	ICCC-3	International Classification of Childhood Cancer, third edition
280	ISPM	Institute of Social and Preventive Medicine
281	SCCR	Swiss Childhood Cancer Registry
282	SPN	Second primary neoplasm

284 Acknowledgements

285 We thank all childhood cancer patients, survivors, and families for participating in our study. We thank the study team of the Childhood Cancer Research Group, Institute of 286 287 Social and Preventive Medicine, University of Bern, and SCCSS (Tomas Slama, 288 Fabienne Luzi, Maria Otth, Selma Riedo), the data managers of the Swiss pediatric 289 oncology clinics (Claudia Althaus, Nadine Assbichler, Pamela Balestra, Heike 290 Baumeler, Nadine Beusch, Sarah Blanc, Pierluigi Brazzola, Susann Drerup, Janine 291 Garibay, Franziska Hochreutener, Monika Imbach, Friedgard Julmy, Eléna Lemmel, 292 Heike Markiewicz, Annette Reinberg, Renate Siegenthaler, Astrid Schiltknecht, Beate 293 Schwenke, and Verena Stahel) and the data managers and administrative staff of the 294 SCCR (Meltem Altun, Erika Brantschen, Katharina Flandera, Elisabeth Kiraly, Verena 295 Pfeiffer, Julia Ruppel, Ursina Roder, and Nadine Lötscher). We thank the study team of 296 the CANSEARCH research platform in paediatric oncology and haematology of the 297 University of Geneva (Khalil Ben Hassine, Simona Jurkovic Mlakar, Vid Mlakar, 298 Shannon Robin), and the Onco-Hematology Unit of the HUG (Frederic Baleydier, 299 Fanette Bernard, André von Bueren, Fabienne Gumy-Pause, Nelly Hafner-Bénichou, 300 Rodolfo Lo Piccolo). 301 302 303 **Competing interests** The authors declare that they have no competing interests 304 305

306 STROBE Checklist: Supplementary File.

307 Funding

- 308 This study is supported by the CANSEARCH Foundation for BISKIDS, the host
- 309 biobank BaHOP, the research study GECCOS, and salary support to Nicolas Waespe
- 310 and Sven Strebel. Further funding comes from the Swiss National Science Foundation
- 311 (31BL30_185396), and Swiss Cancer Research (KFS-4722-02-2019, KLS/KFS-4825-
- 312 01-2019).
- 313 The funding bodies have no role in the design of the study and collection, analysis, and
- 314 interpretation of data and in writing this manuscript.
- 315

316 Ethics approval and consent to participate

- 317 The Geneva Cantonal Commission for Research Ethics has approved the BaHOP
- biobank (approval PB_2017-00533) and the Genetic Risks for Childhood Cancer
- 319 Complications Switzerland (GECCOS) study, which will utilize the samples (approval
- 320 2020-01723).

321

- 322 Trial registration
- 323 Clinicaltrials.gov: NCT04702321
- 324
- 325 Consent for publication
- 326 All participants signed informed consents themselves or through their guardians.

328 Availability of data and materials

329	Datasets ar	e available fr	om the corres	ponding author	on reasonable rec	uest for sp	ecific
541	Dulubelb ur			ponding addition		acot for op	COLLIC

- 330 projects.
- 331
- 332

333 Authors' contributions

- 334 NW: Conceptualization, Design, Methodology, Formal analysis, Data curation, Project
- 335 administration, Writing all stages, Visualization.
- 336 SSt: Project administration, Writing Reviewing and Editing
- 337 FB, LM: Writing Reviewing and Editing
- 338 TN: Conceptualization, Design, Methodology, Writing Reviewing and Editing
- 339 DM, VM: Conceptualization, Data curation, Project administration, Writing -
- 340 Reviewing and Editing
- FM: Data curation, Project administration, Visualisation, Writing Reviewing and
 Editing
- 343 AS: Conceptualization, Design, Methodology, Writing Reviewing and Editing.
- 344 CEK, MA: Supervision, Conceptualization, Design, Methodology, Writing Reviewing345 and Editing.

346

347 All authors have approved the submitted version.

348 **References**

349 350 351	1	Bhatia S, Armenian SH, Armstrong GT, van Dulmen-den Broeder E, Hawkins MM, Kremer LCM, Kuehni CE, Olsen JH, Robison LL, Hudson MM. Collaborative Research in Childhood Cancer Survivorship: The Current Landscape. <i>JCO</i> 2015; 33 :3055–64.
352 353 354 355	2	Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, Green DM, Armstrong GT, Nottage KA, Jones KE, Sklar CA, Srivastava DK, Robison LL. Clinical Ascertainment of Health Outcomes Among Adults Treated for Childhood Cancer. <i>JAMA</i> 2013; 309 :2371–81.
356 357 358 359 360 361	3	Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, Chemaitilly W, Ehrhardt MJ, Bass J, Bishop MW, Shelton K, Lu L, Huang S, Li Z, Caron E, Lanctot J, Howell C, Folse T, Joshi V, Green DM, Mulrooney DA, Armstrong GT, Krull KR, Brinkman TM, Khan RB, Srivastava DK, Hudson MM, Yasui Y, Robison LL. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). <i>The Lancet</i> 2017; 390 :2569–82.
362 363 364	4	Schindler M, Spycher BD, Ammann RA, Ansari M, Michel G, Kuehni CE, for the Swiss Paediatric Oncology Group (SPOG). Cause-specific long-term mortality in survivors of childhood cancer in Switzerland: A population-based study. <i>Int J Cancer</i> 2016; 139 :322–33.
365 366 367 368	5	Ness KK, Li C, Mitby PA, Radloff GA, Mertens AC, Davies SM, Hammond S, Armstrong GT, Robison LL. Characteristics of responders to a request for a buccal cell specimen among survivors of childhood cancer and their siblings. <i>Pediatr Blood Cancer</i> 2010; 55 :165–70.
369 370 371 372 373 374 375 376 377 378 379 380 381	6	Byrne J, Grabow D, Campbell H, O'Brien K, Bielack S, Am Zehnhoff-Dinnesen A, Calaminus G, Kremer L, Langer T, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, Baust K, Bautz A, Beck JD, Berger C, Binder H, Borgmann-Staudt A, Broer L, Cario H, Casagranda L, Clemens E, Deuster D, de Vries A, Dirksen U, Falck Winther J, Fosså S, Font-Gonzalez A, Grandage V, Haupt R, Hecker-Nolting S, Hjorth L, Kaiser M, Kenborg L, Kepak T, Kepáková K, Knudsen LE, Krawczuk-Rybak M, Kruseova J, Kuehni CE, Kunstreich M, Kuonen R, Lackner H, Leiper A, Loeffen EAH, Luks A, Modan-Moses D, Mulder R, Parfitt R, Paul NW, Ranft A, Ruud E, Schilling R, Spix C, Stefanowicz J, Strauβ G, Uitterlinden AG, van den Berg M, van der Kooi A-L, van Dijk M, van Leeuwen F, Zolk O, Zöller D, Kaatsch P, PanCareLIFE consortium. PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health- related quality of life after cancer occurring among children and adolescents. <i>Eur J Cancer</i> 2018; 103 :227–37.
382 383 384 385	7	Wang Z, Wilson CL, Easton J, Thrasher A, Mulder H, Liu Q, Hedges DJ, Wang S, Rusch MC, Edmonson MN, Levy S, Lanctot JQ, Caron E, Shelton K, Currie K, Lear M, Patel A, Rosencrance C, Shao Y, Vadodaria B, Yergeau D, Sapkota Y, Brooke RJ, Moon W, Rampersaud E, Ma X, Chang T-C, Rice SV, Pepper C, Zhou X, Chen X, Chen W, Jones A,

- Rampersaud E, Ivia A, Chang T-C, Kice SV, Fepper C, Zhou A, Chen A, Chen A, Sones A,
 Boone B, Ehrhardt MJ, Krasin MJ, Howell RM, Phillips NS, Lewis C, Srivastava D, Pui CH, Kesserwan CA, Wu G, Nichols KE, Downing JR, Hudson MM, Yasui Y, Robison LL,
- 387 H, Kesserwah CA, Wu G, Nichols KE, Downing JK, Hudson MM, Fasur F, Kobison J
 388 Zhang J. Genetic Risk for Subsequent Neoplasms Among Long-Term Survivors of
- 389 Childhood Cancer. *JCO* 2018;:JCO.2018.77.8589.

- Rogers NL, Cole SA, Lan H-C, Crossa A, Demerath EW. New saliva DNA collection
 method compared to buccal cell collection techniques for epidemiological studies.
 American Journal of Human Biology 2007;19:319–26.
- 393 9 Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of
 394 Childhood Cancer, third edition. *Cancer* 2005;103:1457–67.
- Waespe N, Belle FN, Redmond S, Schindera C, Spycher BD, Rössler J, Ansari M, Kuehni
 CE, Ansari M, Beck-Popovic M, Bourquin J-P, Brazzola P, Greiner J, Rössler J,
 Scheinemann K, Schilling F, Weid N von der. Cancer predisposition syndromes as a risk
 factor for early second primary neoplasms after childhood cancer A national cohort study. *European Journal of Cancer* 2021;145:71–80.
- 400 11 Dykema J, DiLoreto K, Croes KD, Garbarski D, Beach J. Factors Associated with
 401 Participation in the Collection of Saliva Samples by Mail in a Survey of Older Adults.
 402 Public Opinion Quarterly 2017;81:57–85.
- 12 Nishita DM, Jack LM, McElroy M, McClure JB, Richards J, Swan GE, Bergen AW.
 Clinical trial participant characteristics and saliva and DNA metrics. *BMC Medical Research Methodology* 2009;9:71.
- 406 13 Keag OE, Murphy L, Bradley A, Deakin N, Whyte S, Norman JE, Stock SJ. Postal
 407 recruitment for genetic studies of preterm birth: A feasibility study. *Wellcome Open Res*408 2020;5:26.
- 409 14 McElfish PA, Narcisse M-R, Long CR, Ayers BL, Hawley NL, Aitaoto N, Riklon S, Su LJ,
 410 Ima SZ, Wilmoth RO, Schulz TK, Kadlubar S. Leveraging community-based participatory
 411 research capacity to recruit Pacific Islanders into a genetics study. *J Community Genet*412 2017;8:283–91.
- Rueegg CS, Gianinazzi ME, Michel G, Zwahlen M, von der Weid NX, Kuehni CE. No
 evidence of response bias in a population-based childhood cancer survivor questionnaire
 survey Results from the Swiss Childhood Cancer Survivor Study. *PLoS One* 2017;12.
 doi:10.1371/journal.pone.0176442
- 417 16 Brall C, Berlin C, Zwahlen M, Ormond KE, Egger M, Vayena E. Public willingness to
 418 participate in personalized health research and biobanking: A large-scale Swiss survey.
 419 *PLoS ONE* 2021;16:e0249141.
- 420
- 421
- 422

Waespe et al.

Figures

Participation in home DNA sampling

1 **Figure 1.** Flowchart of the response to invitation to the BISKIDS home collection of

2 germline DNA in 928 patients.

